@article{74a377d893d343eeac9b52fce01a60c7,
title = "Understanding the etiology and epidemiology of meningitis and encephalitis: now and into the future",
author = "Vyanka Redenbaugh and Flanagan, {Eoin P.}",
note = "Funding Information: Eoin P. Flanagan - Dr Flanagan has served on advisory boards for Alexion, Genentech and Horizon Therapeutics. He has received speaker honoraria from Pharmacy Times. He received royalties from UpToDate. Dr Flanagan was a site primary investigator in a randomized clinical trial on Inebilizumab in neuromyelitis optica spectrum disorder run by Medimmune/Viela-Bio/Horizon Therapeutics. Dr Flanagan has received funding from the NIH (R01NS113828). Dr Flanagan is a member of the medical advisory board of the MOG project. Dr Flanagan is an editorial board member of the Journal of the Neurological Sciences and Neuroimmunology Reports. A patent has been submitted on DACH1-IgG as a biomarker of paraneoplastic autoimmunity. ",
year = "2022",
month = mar,
doi = "10.1016/j.lanwpc.2021.100380",
language = "English (US)",
volume = "20",
journal = "The Lancet Regional Health - Western Pacific",
issn = "2666-6065",
publisher = "Elsevier Ltd",
}